ArriVent BioPharma, Inc. Common Stock

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for cancers with unmet medical needs. Its lead candidate, firmonertinib, is a tyrosine kinase inhibitor being evaluated in multiple clinical trials for non-small cell lung cancer (NSCLC) with various epidermal growth factor receptor mutations (EGFRm), including a Phase 3 trial for advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations and Phase 1b trials for activating EGFRm, including P-loop and alpha-c-helix compressing (PACC) mutations, and classical EGFRm. The company is also developing ARR-217, an antibody drug conjugate (ADC) for gastrointestinal cancers, and ARR-002, ARR-421, and ARR-173 for solid tumors. It has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. Incorporated in 2021, ArriVent BioPharma is based in Newtown Square, Pennsylvania.